• Microbix Biosystems (TSX:MBX) has announced a distribution agreement with The Medical Supply Company of Ireland (MSC)
  • Under the terms of the agreement, MSC will distribute Microbix’s products to markets in the Republic of Ireland and Northern Ireland
  • MSC will be responsible for the provision of marketing, distribution, and logistical support
  • Microbix Biosystems (MBX) is currently up 4.88 per cent to C$0.22 per share, with a market cap of $23.38 million

Microbix Biosystems (TSX:MBX) has announced a distribution agreement with The Medical Supply Company of Ireland (MSC).

With sales currently in excess of C$1 million per month, Microbix is a developer of biological and technological solutions for human health and well-being.

Under the terms of the agreement, MSC will distribute Microbix’s quality assessment products (QAPs) to markets in the Republic of Ireland and Northern Ireland.

In addition, MSC will be responsible for the provision of marketing, distribution, and logistical support regarding the products.

There are currently four dozen QAPs across the Microbix’s PROCEEDx and REDx Controls tradenames. These products are designed to support the accuracy of tests for bacterial and viral diseases by emulating patient samples.

Phil Casselli, Senior Vice President of Sales and Business Development at Microbix, said that he was pleased to have MSC on board as a partner.

“They are the major provider of laboratory supply materials, diagnostic controls and technical support for the Republic of Ireland and Northern Ireland, with well-trained marketing and sales staff and a team of field service professionals.

“Microbix believes MSC will provide QAPs customers with excellent user training and after sales support for our growing PROCEEDx and REDx Controls product lines,” he added.

MSC is a privately-owned company with an extensive team of sales people. Specially trained, the team provides analytical consumables, diagnostic equipment and other solutions to customers in the life science and clinical diagnostics industry.

Of particular interest to MSC is Microbix’s Human Papilloma Virus (HPV) and Mycoplasma genitalium (MGEN) control products.

The two diseases are prominent in the sexual health testing market, and MSC currently services a number of clinical laboratories performing these tests.

Lisa Tang, Life Sciences Sales Manager at MSC, also commented on the agreement.

“These QAPs will complement our portfolio of controls and supplies for sexually-transmitted, respiratory, gastrointestinal, and hospital-acquired pathogens.

“Training of MSC staff about QAPs is underway and we’re now stocking these products for our customers,” she concluded.

Microbix Biosystems (MBX) is currently up 4.88 per cent to $0.22 per share at 11:49am EST.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.